Core Insights - Renovaro Inc. has entered into a binding Letter of Intent (LOI) to acquire Predictive Oncology in an all-stock transaction, which will enhance its capabilities in cancer diagnostics and therapeutics powered by artificial intelligence [1][2] Short-Term Synergies - The acquisition provides access to a biobank of over 150,000 tumor specimens and 200,000 pathology slides, which will accelerate biomarker discovery and clinical trial optimization [6] - Predictive Oncology's AI/ML platform has a proven accuracy of 92% in predicting tumor-drug responses, which will support oncologists in making informed treatment decisions [2][8] - The combined organization will streamline the development and rollout of new diagnostic tests in Europe, improving speed to market and expanding global reach [6] Long-Term Vision - The integration of Predictive Oncology's drug discovery platform with Renovaro's liquid biopsy approach aims to create a comprehensive solution for cancer diagnostics and personalized therapies [6] - The partnership is expected to advance cancer therapy at every stage of the patient's journey, improving outcomes and reducing costs [6] - The acquisition will enable collaboration across multi-omic platforms for drug discovery, enhancing the overall capabilities of the combined entity [6] Transaction Details - Renovaro will acquire 100% of Predictive Oncology's common shares through the issuance of Preferred stock [7]
Renovaro to Acquire Predictive Oncology in All-Stock Transaction